ArticleCureus2025
PFKP Mediates Breast Cancer Metastasis Through Altered Glycolysis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- ENO1 as a Central Regulator Linking Metabolic Reprogramming to Tumor Plasticity.International journal of molecular sciences · 2026Review
- Targeting phosphofructokinase in cancer: integrating natural products for metabolic reprogramming and therapeutic innovation.Frontiers in pharmacology · 2026Review
- Combined vitamins D3 and K2 as potential modulators of multiple myeloma cell pathophysiology: transcriptomic and epigenetic effects under standard culture and bone marrow-like conditions.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Despite recent breakthroughs in genetic profiling, breast cancer metastasis remains a considerable challenge affecting treatment and overall patient survival. Therefore, the discovery of target alternatives to restrain metastasis is urgently needed. In the current study, we aimed to identify novel targets driving metastasis and elucidate the underlying mechanisms. Methods We initially identified differentially expressed genes between primary breast tumors and metastatic breast cancer patients using datasets from the Gene Expression Omnibus (GEO) database. Subsequently, we validated these findings by examining the changes in gene expression and their direction in external datasets. Furthermore, we identified the significantly enriched pathways associated with gene expression. We analyzed PFKP expression patterns in 100 samples (normal, primary breast tumor, and metastasis) using quantitative real-time polymerase chain reaction (qRT-PCR), and survival analyses were performed. Results We identified 34 differentially expressed genes in metastatic breast tumors, with CCDC6, PKIA, UACA, and PFKP significantly upregulated (p < 0.05). PFKP was highly expressed in metastasis, negatively correlated with ER/PR/HER2 status, and linked to glycolysis-related genes (ENO1, PGM1, LDHB, and PGK1). Gene set enrichment analysis (GSEA) highlighted its role in glucose metabolism, hypoxia, and angiogenesis. qRT-PCR confirmed PFKP (p < 0.001) and Ki67 (p < 0.001) upregulation in 100 breast cancer samples. PFKP correlated with Ki67, and receiver operating characteristic (ROC) analysis (area under the curve (AUC) > 71%) indicated a strong predictive value. Higher PFKP expression was associated with poor survival, supporting its role as a prognostic marker. Conclusion The current study showed that PFKP promotes tumor metastasis through hypoxia-mediated altered glycolysis and can be a potential prognostic marker used to identify breast cancer metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.